Seres Therapeutics Competitors and Similar CompaniesClear all

Seres Therapeutics's competitors and similar companies include Axsome Therapeutics, Phyton Biotech, Tikomed and Kangstem Biotech.

	Seres Therapeutics Seres Therapeutics is a clinical stage biotherapeutic company focused on discovering and developing Ecobiotic™ therapeutic products.	Axsome Therapeutics Axsome Therapeutics is a clinical-stage biopharmaceutical company that develops therapies for the management of central nervous system disorders.	Phyton Biotech Phyton Biotech is a company that specializes in the pharmaceutical plant cell fermentation (PCF) technology.	Tikomed Tikomed is a company that develops treatments for patients with severe and life-threatening conditions.	Kangstem Biotech Kangstem Biotech (강스템바이오텍) is a biopharmaceutical company that focuses on blood-derived stem cell therapy.
Founding Date	Founding Date 2010	Founding Date 2012	Founding Date 2009	Founding Date 2002	Founding Date 2010
Type	Type Public	Type Public	Type Private	Type Private	Type Public
Tags	Tags Healthcare biotech drug development healthtech life sciences pharma therapy	Tags Healthcare biotech clinical research drug development healthtech life sciences pharma therapy	Tags Healthcare biotech drug development life sciences pharma therapy	Tags Healthcare biotech drug development life sciences pharma therapy	Tags Healthcare biotech drug development life sciences pharma therapy
Locations	Locations Cambridge, US HQ	Locations New York, US HQ New York, US	Locations Delta, CA HQ Ahrensburg, DE	Locations Viken, SE HQ	Locations KR HQ
Employees	Employees 23346% decrease	Employees 4111% increase	Employees 1232% increase	Employees 8	Employees 97
Valuation ($)	Valuation ($) 131.2 m	Valuation ($) 4.3 b	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) $789k (FY, 2025)	Revenue (est.) $638.5m (FY, 2025)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) ₩7.7b (FY, 2024)
Net income	Net income $5.7m (FY, 2025)	Net income ($183.2m) (FY, 2025)	Net income N/A	Net income N/A	Net income (₩7.1b) (FY, 2024)
Funding
Total funding raised	Total funding raised $ 113m	Total funding raised $ 7m	Total funding raised N/A	Total funding raised N/A	Total funding raised N/A